Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,253 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,253 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.11, for a total value of $243,219.83. Following the transaction, the chief accounting officer owned 10,352 shares of the company’s stock, valued at $2,009,426.72. This trade represents a 10.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $190.91, for a total value of $213,246.47.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $190.46 on Tuesday. The firm has a market capitalization of $11.72 billion, a PE ratio of -31.90, a P/E/G ratio of 0.38 and a beta of 0.22. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average price of $170.05 and a 200 day moving average price of $152.44. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The company had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the business posted $6.51 EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its stake in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares in the last quarter. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $36,000. Hantz Financial Services Inc. raised its holdings in shares of Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares during the period. LRI Investments LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Finally, Danske Bank A S purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can increase visibility and liquidity for the stock and sometimes leads to upgrades or renewed investor interest. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: A Zacks report examines Jazz’s dependence on international sales and the implications for analyst forecasts and the company’s growth outlook — useful background but not an immediate catalyst unless the analysis triggers revisions to guidance or estimates. Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
• Negative Sentiment: Executive vice president Neena M. Patil sold 55,600 shares (≈$10.65M at ~$191.56/share), a nearly 50% reduction in her stake — a large single insider sale that may weigh on sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); CAO Patricia Carr executed two smaller sales on Feb. 26–27. Collectively these transactions represent meaningful percentage reductions in holdings by multiple insiders and may be interpreted as a near-term negative signal by some investors. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing Patricia Carr SEC Filing

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $214.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.